Phase 3 Osteoarthritis Trial, Recruiting NCT06003101 Sponsor: Massachusetts General Hospital Condition: Osteoarthritis
Back to Osteoarthritis

Phase 3 Osteoarthritis Trial, Recruiting

NCT06003101
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older
  • People for whom a hip arthroscopy (a keyhole procedure to look inside the hip joint) has been recommended by the study's lead doctor to treat a problem with the labrum (the cartilage ring around the hip joint)
  • People who are willing to take part, are comfortable being randomly assigned to either treatment group, and are able to understand and sign the consent form

Who may not be able to join:

  • People who do not speak English, as the survey tools used in the study have only been validated in English
  • People who have previously had surgery on the same hip, including but not limited to a prior hip arthroscopy, core decompression (a procedure to relieve pressure in the hip bone), or a periacetabular osteotomy (a procedure to reposition the hip socket)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Scott D. Martin, MD, Massachusetts General Hospital

Phone: 617-732-5329

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Registry
ClinicalTrials.gov
Start date
30 August 2023
Est. completion
30 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Pain Level; Modified Harris Hip Score (mHHS); International Hip Outcome Tool-12 (iHOT-12); Non-Arthritic Hip Score (NAHS); Hip Outcome Score (HOS); Kerlan-Jobe Orthopaedic Clinic Athletic Hip Score; Visual Analog Scale (VAS) Pain Score

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov